RPA2 and breast carcinoma: Thus, valproic acid, a histone deacetylase inhibitor, and hydroxyurea, a ribonucleotide reductase inhibitor, synergistically sensitize breast cancer cells by perturbing RPA2 hyperphosphorylation and thus HR (339).